Benjamin Cheng
7 Papers
5 Citations
Benjamin Cheng is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).
Matthew D. Galsky,Gianluca Del Conte,Silvia Foti,Evan Y. Yu,Jean-Pascal Machiels,Bernard Doger,Andrea Necchi,Filippo de Braud,Erika Hamilton,Audrey Hennequin,Tom Van den Mooter,Philip R. Debruyne,Irene Moreno,Hendrik-Tobias Arkenau,Zenta Tsuchihashi,Fu-Chih Cheng,Bincy Augustine,Benjamin Cheng,Daniel Barrios,Diana Lüftner +19 more
TL;DR: In this article , a phase 1b, 2-part, open-label, multicenter study of T-DXd in combination with nivo in pts with HER2-expressing advanced/metastatic UC (NCT03523572).
71
162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer
Erika Hamilton,Charles L. Shapiro,Valentina Boni,M. Martin Jimenez,Gianluca Del Conte,Jorge E. Cortes,Laila Saied Agrawal,Hendrik-Tobias Arkenau,A. Tan,Philip R. Debruyne,Anna Minchom,Annemie Rutten,Frances Valdes-Albini,Eric Chi-Wang Yu,F. Suto,Fu-Chih Cheng,Bincy Augustine,Benjamin Cheng,Daniel Barrios,Sara A. Hurvitz +19 more
TL;DR: In this article , T-DXd showed efficacy and safety in pts with HER2+ metastatic breast cancer (MBC) with prior T-DM1, and nivo 360 mg IV Q3W.
30
453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study
Toshihiko Doi,M.R. Patel,Gs. Falchook,Takafumi Koyama,Claire F. Friedman,Sarina Anne Piha-Paul,M. Gutierrez,Raghad M Abdul-Karim,M Awad,Douglas Adkins,J. Takahashi,Shigenori Kadowaki,Benjamin Cheng,Nobumasa Ikeda,A. Laadem,Naoto Yoshizuka,M. Qian,O. J. Dosunmu,Hendrik-Tobias Arkenau,M.L. Johnson +19 more
TL;DR: DS-7300 as discussed by the authors is a B7-H3-directed ADC with a topoisomerase I inhibitor payload (DXd), which showed that it was generally well tolerated with early signs of antitumor activity.
25
A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
Suzanne George,Michael Heinrich,Neeta Somaiah,Brian A. Van Tine,Robert McLeod,Abderrahmane Laadem,Benjamin Cheng,Satoshi Nishioka,Madan G. Kundu,Xia Qian,Yvonne Y. Lau,Brittany Tran,Prasanna Kumar,O. Dosunmu,Julia J. Shi,Yoichi Naito +15 more
TL;DR: DS-6157a was generally well tolerated with early signs of moderate clinical activity and dose-dependent PK exposure was confirmed within the range of dose levels, and progression-free survival across all dose levels was 3.6 months.
5
1550TiP Phase II, multicenter, randomized, open-label study of DS-7300 in patients (pts) with pre-treated extensive-stage small cell lung cancer (ES-SCLC)
Luiz Paz-Ares,M.L. Johnson,N. Girard,Christine L. Hann,M. Ahn,M. Nishio,Joel Godard,A. Laadem,Naoto Yoshizuka,Minjia Qian,Benjamin Cheng,Charles M. Rudin +11 more
TL;DR: DS-7300 as discussed by the authors is a novel antibody drug conjugate comprising a humanized anti-B7-H3 immunoglobulin G1 monoclonal antibody and potent topoisomerase I inhibitor payload (exatecan derivative, DXd) covalently linked by a stable tetrapeptide-based cleavable linker.
3